To evaluate tumors in this range further, we unblinded our results and re-scored tumors based on consensus discussion and additional criteria (re-evaluation of tumor cellularity on H&E with exclusion of mostly normal-appearing areas, additional p16 staining where suboptimal, consideration of weak cytoplasmic staining as positive, recognition and exclusion of background non-neoplastic staining) (Figs. 2 and 4). This evidence concerns the gene CDKN2A and neoplasm.